28069611|t|Bioresorbable Vascular Scaffolds for the Treatment of Chronic Total Occlusions: An International Multicenter Registry
28069611|a|There are only limited studies reporting clinical outcomes after bioresorbable vascular scaffold (BVS; Absorb; Abbott Vascular, Santa Clara, CA) implantation for coronary chronic total occlusions (CTO). The aim of this study was to evaluate the real-world feasibility and safety of BVS implantation for the treatment of CTO. We retrospectively evaluated CTO cases treated with BVS from a multicenter registry. The primary end point was target lesion failure defined as a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization. From September 2012 to November 2015, 65 patients with CTO were successfully treated with BVS. The mean age of patients was 60.8±11.0 years; 89.2% were male and 40.0% diabetic. The mean ejection fraction was 57.7±10.8%. The mean reference vessel diameter and CTO lesion length were 3.0±0.4 and 20.2±3.0 mm, respectively. The mean number of BVS deployed per patient was 1.8±0.7, of which mean diameter and total length were 3.0±0.4 and 47.6±19.9 mm, respectively. Postdilatation with noncompliant balloons (mean diameter 3.3±0.3 mm) was performed at high pressures (18.6±5.3 atm) in all cases. Intravascular ultrasound (n=34) or optical coherence tomography (n=31) was performed in all cases. During the follow-up period (median: 453 days, 25th and 75th percentiles: 230 and 703), there were no occurrences of target lesion failure or scaffold thrombosis. BVS implantation for the treatment of CTO seems feasible and safe. Appropriate lesion preparation, high-pressure postdilatation, and the use of intravascular imaging are recommended to obtain the best possible final result.
28069611	0	32	Bioresorbable Vascular Scaffolds	T074	C4264469
28069611	41	50	Treatment	T169	C0039798
28069611	54	78	Chronic Total Occlusions	T047	C3275069
28069611	83	117	International Multicenter Registry	T170	C0034975
28069611	159	167	clinical	T080	C0205210
28069611	168	176	outcomes	T080	C0085415
28069611	183	214	bioresorbable vascular scaffold	T074	C4264469
28069611	216	219	BVS	T074	C4264469
28069611	229	244	Abbott Vascular	T073,T092	C0683757
28069611	246	261	Santa Clara, CA	T083	C3828240
28069611	263	275	implantation	T061	C0021107
28069611	280	288	coronary	T023	C0018787
28069611	289	313	chronic total occlusions	T047	C3275069
28069611	315	318	CTO	T047	C3275069
28069611	350	358	evaluate	T058	C0220825
28069611	363	385	real-world feasibility	T062,T170	C0015730
28069611	390	396	safety	T058	C0014680
28069611	400	403	BVS	T074	C4264469
28069611	404	416	implantation	T061	C0021107
28069611	425	434	treatment	T169	C0039798
28069611	438	441	CTO	T047	C3275069
28069611	446	461	retrospectively	T062	C0035363
28069611	462	471	evaluated	T058	C0220825
28069611	472	475	CTO	T047	C3275069
28069611	482	494	treated with	T061	C0332293
28069611	495	498	BVS	T074	C4264469
28069611	506	526	multicenter registry	T170	C0034975
28069611	540	549	end point	T080	C2349179
28069611	554	560	target	T029	C0449618
28069611	561	567	lesion	T033	C3272304
28069611	568	575	failure	T169	C0231174
28069611	589	598	composite	T080	C0205199
28069611	602	615	cardiac death	T046	C0376297
28069611	617	630	target vessel	T029	C0449618
28069611	631	652	myocardial infarction	T047	C0027051
28069611	658	675	clinically driven	T080	C0205210
28069611	676	682	target	T029	C0449618
28069611	683	689	lesion	T033	C3272304
28069611	690	707	revascularization	T061	C0027056
28069611	750	758	patients	T101	C0030705
28069611	764	767	CTO	T047	C3275069
28069611	786	798	treated with	T061	C0332293
28069611	799	802	BVS	T074	C4264469
28069611	820	828	patients	T101	C0030705
28069611	861	865	male	T032	C0086582
28069611	876	884	diabetic	T201	C1315719
28069611	895	912	ejection fraction	T033	C2700378
28069611	933	963	mean reference vessel diameter	T082	C3898449
28069611	968	971	CTO	T047	C3275069
28069611	972	985	lesion length	T033	C1443266
28069611	1049	1052	BVS	T074	C4264469
28069611	1053	1061	deployed	T052	C3640039
28069611	1066	1073	patient	T101	C0030705
28069611	1172	1213	Postdilatation with noncompliant balloons	T061	C0002997
28069611	1245	1254	performed	T169	C0884358
28069611	1258	1272	high pressures	T067	C0563294
28069611	1302	1326	Intravascular ultrasound	T060	C1456025
28069611	1337	1365	optical coherence tomography	T060	C0920367
28069611	1377	1386	performed	T169	C0884358
28069611	1412	1421	follow-up	T058	C1522577
28069611	1422	1428	period	T079	C1948053
28069611	1500	1502	no	T169	C1518422
28069611	1503	1514	occurrences	T079	C2745955
28069611	1518	1524	target	T029	C0449618
28069611	1525	1531	lesion	T033	C3272304
28069611	1532	1539	failure	T169	C0231174
28069611	1543	1562	scaffold thrombosis	T046	C3897493
28069611	1564	1567	BVS	T074	C4264469
28069611	1568	1580	implantation	T061	C0021107
28069611	1589	1598	treatment	T169	C0039798
28069611	1602	1605	CTO	T047	C3275069
28069611	1643	1649	lesion	T033	C3272304
28069611	1663	1676	high-pressure	T067	C0563294
28069611	1677	1691	postdilatation	T061	C0004704
28069611	1708	1729	intravascular imaging	T060	C1456016
28069611	1780	1786	result	T169	C1274040